New drug combo shows promise in early breast cancer trial

NCT ID NCT01597388

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This early-phase study tested the safety of an experimental drug (AZD2014) combined with a standard hormone therapy (fulvestrant) in 99 people with advanced, estrogen receptor-positive breast cancer. The main goal was to see if the combination is safe and tolerable, not to cure the disease. Participants had to have measurable tumors and be eligible for fulvestrant treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Sarasota, Florida, 34232, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Oklahoma City, Oklahoma, 73104, United States
Research Site

Greenville, South Carolina, 29605, United States
Research Site

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED METASTATIC BREAST CANCER